George Perry

101.7k total citations · 18 hit papers
905 papers, 69.0k citations indexed

About

George Perry is a scholar working on Physiology, Molecular Biology and Pharmacology. According to data from OpenAlex, George Perry has authored 905 papers receiving a total of 69.0k indexed citations (citations by other indexed papers that have themselves been cited), including 503 papers in Physiology, 381 papers in Molecular Biology and 131 papers in Pharmacology. Recurrent topics in George Perry's work include Alzheimer's disease research and treatments (468 papers), Cholinesterase and Neurodegenerative Diseases (123 papers) and Mitochondrial Function and Pathology (109 papers). George Perry is often cited by papers focused on Alzheimer's disease research and treatments (468 papers), Cholinesterase and Neurodegenerative Diseases (123 papers) and Mitochondrial Function and Pathology (109 papers). George Perry collaborates with scholars based in United States, Japan and Portugal. George Perry's co-authors include Mark A. Smith, Xiongwei Zhu, Akihiko Nunomura, Lawrence M. Sayre, Hyoung‐gon Lee, Rudy J. Castellani, Xinglong Wang, Paula I. Moreira, Peggy L.R. Harris and Sandra L. Siedlak and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

George Perry

888 papers receiving 67.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oxidative Damage Is the Earliest Event in Alzheimer Disease

2001 1.5k citations Akihiko Nunomura, George Perry et al. profile →
Mitochondrial Abnormalities in Alzheimer's Disease

2001 1.1k citations Keisuke Hirai, Gjumrakch Aliev et al. profile →
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals

1997 1.1k citations Mark A. Smith, George Perry et al. profile →
The Amyloid-β Pathway in Alzheimer’s Disease

2021 1.1k citations Harald Hampel, George Perry et al. profile →
Oxidative stress and mitochondrial dysfunction in Alzheimer's disease

2013 1.1k citations Xinglong Wang, George Perry et al. profile →
Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease

1997 1.0k citations George Perry et al. profile →
Impaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease

2009 1.0k citations Xinglong Wang, Hyoung‐gon Lee et al. profile →
4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease

1997 843 citations George Perry et al. profile →
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: recent advances

2020 832 citations George Perry, Xiongwei Zhu et al. profile →
Oxidative stress in Alzheimer’s disease

2000 724 citations Mark A. Smith, Akihiko Nunomura et al. profile →
Oxidative Stress and Neurotoxicity

2007 690 citations George Perry, Mark A. Smith et al. profile →
RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer’s Disease

1999 614 citations George Perry, Keisuke Hirai et al. profile →
Advanced Maillard reaction end products are associated with Alzheimer disease pathology.

1994 608 citations Mark A. Smith, George Perry et al. profile →
Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology

2009 585 citations Xiongwei Zhu, Mark A. Smith et al. profile →
Parkinson's Disease Is Associated with Oxidative Damage to Cytoplasmic DNA and RNA in Substantia Nigra Neurons

1999 513 citations Jing Zhang, George Perry et al. American Journal Of Pathology profile →
Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains.

1987 512 citations George Perry et al. profile →
Chemistry and Biochemistry of Oxidative Stress in Neurodegenerative Disease

2001 508 citations Mark A. Smith, George Perry et al. profile →
Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US

2024 61 citations William Yang Wang, Xin Qi et al. profile →

Peers

Countries citing papers authored by George Perry

Since Specialization

Citations

This map shows the geographic impact of George Perry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Perry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Perry more than expected).

Fields of papers citing papers by George Perry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George Perry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Perry. The network helps show where George Perry may publish in the future.

Co-authorship network of co-authors of George Perry

This figure shows the co-authorship network connecting the top 25 collaborators of George Perry. A scholar is included among the top collaborators of George Perry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Perry. George Perry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study 2025 ·Journal of Alzheimer s Disease ·William Yang Wang, Pamela B. Davis, Xin Qi, Mark E. Gurney, George Perry, Nora D. Volkow, David C. Kaelber, Rong Xu	4
2	The Amyloid Cascade Hypothesis 2024 ·American Journal Of Pathology ·Rudolph J. Castellani, Pouya Jamshidi, Germán Plascencia‐Villa, George Perry	7
3	Label-Free In Situ Chemical Characterization of Amyloid Plaques in Human Brain Tissues 2024 ·ACS Chemical Neuroscience ·James Everett, Jake Brooks, (unknown), Frederik Lermyte, Ian Hands-Portman, Germán Plascencia‐Villa, George Perry, Peter J. Sadler, Peter B. O’Connor, Joanna F. Collingwood, Neil D. Telling	5
4	Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against α-synuclein and 2N4R tau 2024 ·Bioorganic & Medicinal Chemistry ·(unknown), (unknown), (unknown), Arati Tripathi, Germán Plascencia‐Villa, (unknown), George Perry, Ulf Dettmer, Jessica S. Fortin	0
5	Fabrication and Characterization of Quad-Component Bioinspired Hydrogels to Model Elevated Fibrin Levels in Central Nervous Tissue Scaffolds 2024 ·Gels ·(unknown), (unknown), Andrea C. Jimenez‐Vergara, (unknown), (unknown), Wendy Ortega-Lara, Cody O. Crosby, Jennifer M. Steele, Germán Plascencia‐Villa, George Perry, Dany J. Munoz‐Pinto	1
6	Roles of Oxidative Stress in Synaptic Dysfunction and Neuronal Cell Death in Alzheimer’s Disease 2023 ·Antioxidants ·Germán Plascencia‐Villa, George Perry	70
7	Exploring Molecular Targets for Mitochondrial Therapies in Neurodegenerative Diseases 2023 ·International Journal of Molecular Sciences ·Germán Plascencia‐Villa, George Perry	15
8	Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on α-Synuclein and Tau Aggregation 2023 ·ACS Chemical Neuroscience ·(unknown), (unknown), (unknown), (unknown), (unknown), Germán Plascencia‐Villa, (unknown), (unknown), Arati Tripathi, (unknown), Xiongwei Zhu, Jean‐Christophe Rochet, Min‐Hao Kuo, Scott Counts, George Perry, Ulf Dettmer, Cristian A. Lasagna‐Reeves, Jessica S. Fortin	3
9	FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls 2023 ·Diagnostics ·Poul Flemming Høilund‐Carlsen, Mona‐Elisabeth Revheim, Tommaso Costa, Kasper P. Kepp, Rudolph J. Castellani, George Perry, Abass Alavi, Jorge R. Barrio	10
10	Alzheimer’s and Consciousness: How Much Subjectivity Is Objective? 2021 ·SHILAP Revista de lepidopterología ·Vladan Bajić, (unknown), Ivana M. Stanković, Božidarka Zarić, George Perry	1
11	Biogenic metallic elements in the human brain? 2021 ·Science Advances ·James Everett, Frederik Lermyte, Jake Brooks, (unknown), Germán Plascencia‐Villa, Ian Hands-Portman, Jane M. Donnelly, (unknown), George Perry, Xiongwei Zhu, Peter J. Sadler, Peter B. O’Connor, Joanna F. Collingwood, Neil D. Telling	67
12	Omics sciences for systems biology in Alzheimer’s disease: State-of-the-art of the evidence 2021 ·Ageing Research Reviews ·Harald Hampel, Robert Nisticò, Nicholas T. Seyfried, Allan I. Levey, Erica Modeste, Pablo Lemercier, Filippo Baldacci, Nicola Toschi, Francesco Garaci, George Perry, Enzo Emanuele, Pedro L. Valenzuela, Alejandro Lucía, Andrea Urbani, Giulia Maria Sancesario, Mark Mapstone, Massimo Corbo, Andrea Vergallo, Simone Lista	97
13	Transplantation of Human Chorion-Derived Cholinergic Progenitor Cells: a Novel Treatment for Neurological Disorders 2018 ·Molecular Neurobiology ·Alireza Mohammadi, (unknown), (unknown), Peiman Brouki Milan, (unknown), Farshid Sefat, Koorosh Shahpasand, Mansoureh Soleimani, (unknown), (unknown), Faezeh Faghihi, Mohammad Taghi Joghataei, George Perry, Masoud Mozafari	9
14	Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer’s and other neurodegenerative diseases 2013 ·Translational Psychiatry ·Prashant Bharadwaj, Kristyn A. Bates, Tenielle Porter, (unknown), George Perry, John Steele, Sam Gandy, David Groth, Ralph N. Martins, Giuseppe Verdile	61
15	Amyloid-β-Derived Diffusible Ligands Cause Impaired Axonal Transport of Mitochondria in Neurons 2010 ·Neurodegenerative Diseases ·Xinglong Wang, George Perry, Mark A. Smith, Xiongwei Zhu	109
16	Treatment advances in Alzheimer's disease based on the oxidative stress model 2009 ·F1000 Medicine Reports ·Avi L. Friedlich, Raj K. Rolston, Xiongwei Zhu, Michael W. Marlatt, Rudy J. Castellani, Akihiko Nunomura, Hyoung‐gon Lee, Gemma Casadesús, George Perry, Mark A. Smith	1
17	Compensatory responses induced by oxidative stress in Alzheimer disease 2006 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mark A. Smith, George Perry	4
18	Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of τ Filament Formation 2003 ·American Journal Of Pathology ·Ayla Cash, Gjumrakch Aliev, Sandra L. Siedlak, Akihiko Nunomura, Hisashi Fujioka, Xiongwei Zhu, Arun K. Raina, Harry V. Vinters, Massimo Tabaton, Toby Johnson, (unknown), Jesús Ávila, Paul K. Jones, Rudy J. Castellani, Mark A. Smith, George Perry	241
19	Oxidative damage in Alzheimer's disease: the metabolic dimension 2000 ·International Journal of Developmental Neuroscience ·George Perry, Akihiko Nunomura, Keisuke Hirai, Atsushi Takeda, Gjumrakch Aliev, Mark A. Smith	96
20	RNA Oxidation in Alzheimer and Parkinson Diseases 1999 ·Akihiko Nunomura, George Perry, Jing Zhang, Thomas J. Montine, Atsushi Takeda, Shigeru Chiba, Mark A. Smith	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact